MX2011009506A - Antagonista del receptor mineralcorticoide y metodos de uso. - Google Patents
Antagonista del receptor mineralcorticoide y metodos de uso.Info
- Publication number
- MX2011009506A MX2011009506A MX2011009506A MX2011009506A MX2011009506A MX 2011009506 A MX2011009506 A MX 2011009506A MX 2011009506 A MX2011009506 A MX 2011009506A MX 2011009506 A MX2011009506 A MX 2011009506A MX 2011009506 A MX2011009506 A MX 2011009506A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- methods
- receptor antagonist
- mineralocorticoid receptor
- pharmaceutically acceptable
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15957809P | 2009-03-12 | 2009-03-12 | |
| PCT/US2010/026138 WO2010104721A1 (en) | 2009-03-12 | 2010-03-04 | Mineralocorticoid receptor antagonist and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011009506A true MX2011009506A (es) | 2011-09-28 |
Family
ID=42139981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011009506A MX2011009506A (es) | 2009-03-12 | 2010-03-04 | Antagonista del receptor mineralcorticoide y metodos de uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8658638B2 (enExample) |
| EP (1) | EP2406252B1 (enExample) |
| JP (1) | JP5570536B2 (enExample) |
| KR (1) | KR101312179B1 (enExample) |
| CN (1) | CN102333773B (enExample) |
| AU (1) | AU2010222902B2 (enExample) |
| BR (1) | BRPI1009257A2 (enExample) |
| CA (1) | CA2751901C (enExample) |
| EA (1) | EA019179B1 (enExample) |
| ES (1) | ES2542001T3 (enExample) |
| MX (1) | MX2011009506A (enExample) |
| WO (1) | WO2010104721A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| ME03316B (me) | 2014-06-30 | 2019-10-20 | Astrazeneca Ab | Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| EP4118235B1 (en) | 2020-03-11 | 2026-08-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| DE602004014640D1 (de) * | 2003-12-19 | 2008-08-07 | Lilly Co Eli | Tricyclische modulatoren von nuklearen steroidhormonrezeptoren |
| TWI431010B (zh) * | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
-
2010
- 2010-03-04 WO PCT/US2010/026138 patent/WO2010104721A1/en not_active Ceased
- 2010-03-04 MX MX2011009506A patent/MX2011009506A/es active IP Right Grant
- 2010-03-04 JP JP2011554083A patent/JP5570536B2/ja not_active Expired - Fee Related
- 2010-03-04 EA EA201171125A patent/EA019179B1/ru not_active IP Right Cessation
- 2010-03-04 BR BRPI1009257A patent/BRPI1009257A2/pt not_active IP Right Cessation
- 2010-03-04 CA CA2751901A patent/CA2751901C/en not_active Expired - Fee Related
- 2010-03-04 KR KR1020117021231A patent/KR101312179B1/ko not_active Expired - Fee Related
- 2010-03-04 EP EP20100707770 patent/EP2406252B1/en not_active Not-in-force
- 2010-03-04 CN CN201080009314.8A patent/CN102333773B/zh not_active Expired - Fee Related
- 2010-03-04 US US13/203,518 patent/US8658638B2/en not_active Expired - Fee Related
- 2010-03-04 AU AU2010222902A patent/AU2010222902B2/en not_active Ceased
- 2010-03-04 ES ES10707770.3T patent/ES2542001T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2751901A1 (en) | 2010-09-16 |
| JP5570536B2 (ja) | 2014-08-13 |
| EA019179B1 (ru) | 2014-01-30 |
| EP2406252A1 (en) | 2012-01-18 |
| BRPI1009257A2 (pt) | 2016-03-08 |
| US20110312954A1 (en) | 2011-12-22 |
| ES2542001T3 (es) | 2015-07-29 |
| EA201171125A1 (ru) | 2012-02-28 |
| US8658638B2 (en) | 2014-02-25 |
| KR20110124305A (ko) | 2011-11-16 |
| CN102333773A (zh) | 2012-01-25 |
| KR101312179B1 (ko) | 2013-09-26 |
| AU2010222902A1 (en) | 2011-08-11 |
| CA2751901C (en) | 2013-08-06 |
| EP2406252B1 (en) | 2015-05-20 |
| CN102333773B (zh) | 2014-04-16 |
| WO2010104721A1 (en) | 2010-09-16 |
| AU2010222902B2 (en) | 2013-04-18 |
| JP2012520302A (ja) | 2012-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY150474A (en) | 6h-dibenzo [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antogonists | |
| MX2009006795A (es) | Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| MX2010004503A (es) | Compuesto de oxadiazolidinediona. | |
| MX336881B (es) | Compuestos heterociclicos triciclicos. | |
| MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
| WO2008060907A3 (en) | Pyrrolo-pyridine kinase inhibitors | |
| MX346186B (es) | Inhibidores de proteina cinasas. | |
| ATE457979T1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| WO2007135527A3 (en) | Benzimidazolyl compounds | |
| WO2008012622A3 (en) | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor | |
| WO2012177481A3 (en) | Fibroblast growth factor receptor inhibition for the treatment of disease | |
| MX2011013016A (es) | Derivados de aminopirrolidinona y usos de los mismos. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| IN2012DN03182A (enExample) | ||
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| IN2012DN03042A (enExample) | ||
| WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof | |
| MY181731A (en) | Azole benzene derivative | |
| DK2150530T3 (da) | Substituerede sulfonamid-derivater | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2011044375A3 (en) | Apogossypolone derivatives as anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |